Utah Medical Products, Inc. (UTMD) 股票分析

公司概述

Utah Medical Products, Inc. operates as a specialized manufacturer and distributor of medical devices within the healthcare sector, specifically targeting the medical instruments and supplies industry in the United States, Europe, and international markets. The company's product portfolio is designed to support critical functions in labor and delivery, including fetal monitoring accessories, vacuum-assisted delivery systems, various labor and delivery tools, DISPOSA-HOOD infant respiratory hoods, and DELTRAN PLUS blood products. As of the latest available data, the entity maintains a market capitalization of $206.73 million and employs approximately 140 individuals to facilitate its global operations. With annual revenue reaching $38.52 million, the company's financial scale indicates a mid-cap position within the healthcare supply chain, suggesting it serves as a niche provider rather than a dominant market leader in broad medical categories.

财务健康

The company reported trailing twelve-month (TTM) revenue of $38.52 million, generating net income of $11.29 million and an EBITDA of $15.71 million, which highlights a robust cost structure where operating expenses and taxes consume a significant portion of the top line. Specifically, the difference between revenue and net income reveals that the company retains approximately 29.3% of its sales as profit after all expenses, including interest and taxes, are deducted. Free cash flow stands at $11.13 million, a figure that underscores the company's strong financial flexibility and its ability to fund operations, invest in capital expenditures, or return capital to shareholders without relying heavily on external financing. The company demonstrates high profitability efficiency with a gross margin of 57.1%, an operating margin of 31.2%, and a profit margin of 29.3%, indicating effective pricing power and cost control across its supply chain. In terms of leverage, Utah Medical Products holds substantial cash reserves of $85.76 million against a relatively minimal debt load of $285,000, resulting in a conservative debt-to-equity ratio of 0.24. This liquidity position is further reinforced by a current ratio of 37.62, which signals an exceptionally strong ability to meet short-term obligations with its current assets. Additionally, the return on equity is 9.5% and the return on assets is 6.5%, metrics that reflect the management team's effectiveness in generating returns relative to the shareholders' equity and the total asset base utilized.

估值评估

Utah Medical Products, Inc. currently trades with a trailing P/E ratio of 18.54, while a forward P/E ratio is not available, implying that market expectations for future earnings growth have not yet been quantified in a consensus forward model or that analysts lack sufficient data to project next year's earnings accurately. The price-to-book ratio is recorded at 1.72, suggesting that the market values the company at a 72% premium over its tangible book value, which often reflects intangible assets or growth expectations not captured on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 5.37 and an EV/EBITDA of 7.64, indicating that investors are willing to pay a moderate multiple relative to sales and enterprise value adjusted for earnings before interest, taxes, depreciation, and amortization. Regarding price volatility, the stock has fluctuated between a 52-week low of $51.26 and a 52-week high of $68.71, providing a clear range within which the current trading price must be evaluated to determine if it is near recent resistance or support levels. The stock exhibits a beta of 0.35, which indicates that the share price is significantly less volatile than the broader market, moving with roughly one-third of the magnitude of market swings, thereby offering a lower-risk profile for risk-averse portfolios.

Growth & Income

Recent performance data shows a revenue growth rate of -1.2% year-over-year and an earnings growth rate of -6.4% year-over-year, indicating that earnings are declining at a faster pace than revenue, a pattern that often suggests rising operating costs or pricing pressure impacting the bottom line more severely than the top line. The company offers a dividend yield of 1.9% with a payout ratio of 35.2%, a combination that suggests the dividend is well-covered by current earnings and is likely sustainable given the low payout percentage leaves ample room for reinvestment or retention during downturns. Although the recent growth rates are negative, the substantial free cash flow and cash reserves allow the firm to maintain its income profile even in the absence of top-line expansion. Overall, the company presents a profile characterized by high profitability margins and a low-risk volatility profile, though it is currently experiencing a contraction in both sales and earnings growth.